Chinook Thera

$15.42 0.00% ($0.00)

Get ready to invest

About Chinook Thera

Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.

Popular Stocks	Price	Change
Nu Holdings NU	$4.03 14.16%	14.16%
AMC AMC	$14.43 17.99%	17.99%
AMD AMD	$102.26 3.55%	3.55%
Nvidia NVDA	$188.11 5.38%	5.38%
Gap, Inc., The GPS	$11.6 4.32%	4.32%
Snap SNAP	$15.58 5.2%	5.2%
Ford F	$13.63 3.89%	3.89%
Apple AAPL	$149.64 4.08%	4.08%
Grab Holdings inc. GRAB	$2.41 3.88%	3.88%
NIO NIO	$16.57 3.37%	3.37%